U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.

HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...

On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...

Merck MRK continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the prevention of certain cancers caused by human papillomavirus. Though the vaccine’s ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...